LEADER 04023nam  22006615  450 
001 9910298336303321
005 20200702125853.0
010   $a3-7091-1818-2
024 7 $a10.1007/978-3-7091-1818-4
035   $a(CKB)3710000000281304
035   $a(EBL)1966148
035   $a(OCoLC)899003845
035   $a(SSID)ssj0001385856
035   $a(PQKBManifestationID)11883459
035   $a(PQKBTitleCode)TC0001385856
035   $a(PQKBWorkID)11340615
035   $a(PQKB)10064177
035   $a(MiAaPQ)EBC1966148
035   $a(DE-He213)978-3-7091-1818-4
035   $a(PPN)18308778X
035   $a(EXLCZ)993710000000281304
100   $a20141113d2014      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aNovel Technologies for Vaccine Development /$fedited by Igor S Lukashevich, Haval Shirwan
205   $a1st ed. 2014.
210  1$aVienna :$cSpringer Vienna :$cImprint: Springer,$d2014.
215   $a1 online resource (393 p.)
300   $aDescription based upon print version of record.
311   $a3-7091-1817-4 
320   $aIncludes bibliographical references at the end of each chapters.
327   $aReverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines -- Viral-Vectored Vaccines to Control Pathogenic Filoviruses -- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention -- Current Status and Future of Polio Vaccines and Vaccination -- Current Status of Hantavirus Vaccines Development -- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses -- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines -- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines -- Radiovirotherapy for the Treatment of Cancer -- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer -- The Use of Oncolytic Herpesvirus for the Treatment of Cancer -- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.
330   $aThis book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a ?must read? for all those involved in vaccine development, both in academia and industrial vaccine development.
606   $aVaccines
606   $aPharmaceutical technology
606   $aImmunology
606   $aVaccine$3https://scigraph.springernature.com/ontologies/product-market-codes/B16010
606   $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010
606   $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000
615  0$aVaccines.
615  0$aPharmaceutical technology.
615  0$aImmunology.
615 14$aVaccine.
615 24$aPharmaceutical Sciences/Technology.
615 24$aImmunology.
676   $a610
676   $a615.19
676   $a615372
676   $a616079
702   $aLukashevich$b Igor S$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aShirwan$b Haval$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910298336303321
996   $aNovel Technologies for Vaccine Development$92498397
997   $aUNINA